BFLY — Butterfly Network, Inc.
Is BFLY overbought or oversold? Here is the current MarketMoodz read.
Butterfly Network, Inc. (BFLY) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $5.71. The rating moved from Neutral to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$5.71
- Last changeMoved from Neutral to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Butterfly Network’s differentiated handheld ultrasound platform and software-driven revenue model position the company to capture share in point-of-care and outpatient imaging markets. Growth catalysts include expanding device installs, recurring software/consumable sales, and partnerships that leverage the shift of care to outpatient and at-home settings. Near-term performance will be driven by execution on commercial scale-up, unit economics improvement, and capital management. Material risks remain around financing/dilution, competitive pressure from legacy imaging vendors, reimbursement dynamics, and the operational demands of broader adoption. Market sentiment is currently supportive of growth health-tech names, which could amplify upside if key operational milestones are met; conversely, any financing or execution setbacks could drive outsized volatility.
Key factors
- Proprietary single-probe, whole-body ultrasound platform that targets point-of-care and outpatient adoption, creating a differentiated product offering vs. legacy cart systems
- Revenue growth potential from expanding device installs, recurring software/services and consumables, and potential enterprise/telehealth partnerships
- Favorable market backdrop for growth-oriented health-tech names amid risk-on sentiment and sector flows into innovative diagnostics and outpatient care themes
- Readthroughs from sector trends (shift to outpatient/home care and specialty distribution) support addressable market expansion for portable imaging
- Operational levers to scale commercial footprint internationally and among non-traditional buyers (primary care, urgent care, paramedics) offer medium-term upside
Risks
- Capital intensity and cash burn that may require additional financing, creating dilution risk and downward pressure on the stock
- Intense competition from entrenched medical-imaging incumbents and lower-cost ultrasound alternatives, which could compress pricing and margins
- Reimbursement uncertainty and slower-than-expected provider adoption cycles could delay revenue realization from device installs and software subscriptions
- Execution risk on commercial scale-up (salesforce effectiveness, channel partnerships, supply chain) in the face of limited public-company operating history
- Regulatory or product performance setbacks, and limited public social/research sentiment data to validate sustained demand signals
- Sector-specific macro/credit conditions (e.g., convertible-debt dynamics) that can increase volatility and financing costs for mid-cap diagnostics/medtech issuers
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for BFLY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.